John Rondoni - 06 Feb 2023 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Signature
/s/ Bryan Phillips, Attorney-in-Fact for John Rondoni
Issuer symbol
INSP
Transactions as of
06 Feb 2023
Net transactions value
-$1,546,010
Form type
4
Filing time
08 Feb 2023, 16:12:20 UTC
Previous filing
09 Jan 2023
Next filing
14 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Sale $122,049 -490 -3.2% $249.08 14,601 06 Feb 2023 Direct F1, F2
transaction INSP Common Stock Sale $424,847 -1,700 -12% $249.91 12,901 06 Feb 2023 Direct F1, F3
transaction INSP Common Stock Sale $237,943 -949 -7.4% $250.73 11,952 06 Feb 2023 Direct F1, F4
transaction INSP Common Stock Sale $90,871 -361 -3% $251.72 11,591 06 Feb 2023 Direct F1, F5
transaction INSP Common Stock Sale $249,100 -940 -8.1% $265.00 10,651 08 Feb 2023 Direct F1
transaction INSP Common Stock Sale $421,200 -1,560 -15% $270.00 9,091 08 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.34 to $249.28, inclusive. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.41 to $250.40, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.42 to $251.34, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.42 to $252.06, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.